NYSEARCA:PBE Invesco Biotechnology & Genome ETF (PBE) Price, Holdings, & News $61.11 +0.87 (+1.44%) As of 04:10 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartDividendHoldingsOwnershipRatingsBuy This Stock About Invesco Biotechnology & Genome ETF (NYSEARCA:PBE) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get PBE alerts:Sign Up Key Stats Today's Range$59.96▼$61.1150-Day Range$56.01▼$68.3752-Week Range$54.52▼$72.84Volume6,934 shsAverage Volume7,850 shsMarket Capitalization$220.00 millionAssets Under Management$216.45 millionDividend Yield0.07%Net Expense Ratio0.58%Aggregate RatingModerate Buy ETF OverviewPowerShares Dynamic Biotechnology & Genome Portfolio (the Fund) is based on the Dynamic Biotechnology & Genome Intellidex Index (the Index). The Fund seeks investment results that correspond generally to the price and yield of the Index. The Index consists of stocks of 30 the United States biotechnology and genome companies. The Fund will normally invest at least 90% of its total assets in common stocks that consists of the Index. The Index is designed to provide capital appreciation by evaluating companies based on a variety of investment merit criteria, including fundamental growth, stock valuation, investment timeliness and risk factors. Invesco PowerShares Capital Management LLC acts as the Fund's investment adviser.Read More… Invesco Biotechnology & Genome ETF ExpensesTypePBEHealth Care ETFsEquity ETFsNYSEARCA ETFsAll ETFsManagement Fee0.50%0.57%0.56%0.51%0.53%Other Expenses0.08%0.30%0.48%0.56%0.52%Total Expense0.58%0.70%0.72%0.73%0.71%Fee Waiver0.00%-0.45%-0.49%-0.66%-0.54%Net Expense0.58%0.61%0.63%0.58%0.60% Receive PBE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Invesco Biotechnology & Genome ETF and its competitors with MarketBeat's FREE daily newsletter. Email Address PBE ETF News HeadlinesPBE Invesco Biotechnology & Genome ETFJanuary 29, 2025 | seekingalpha.comInvesco Dynamic Biotech & Genome ETF (PBE)August 31, 2024 | uk.finance.yahoo.comNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again. April 24, 2025 | Porter & Company (Ad)Invesco Dynamic Biotechnology & Genome ETF declares quarterly distribution of $0.0242March 22, 2024 | msn.com3 Biotech Stocks to Buy That Have CRISPR-Like Breakthrough PotentialFebruary 19, 2024 | investorplace.comWhere Are Biotech ETFs Headed After Q4 Earnings?February 14, 2024 | msn.comSee More Headlines PBE ETF - Frequently Asked Questions How have PBE shares performed this year? Invesco Biotechnology & Genome ETF's stock was trading at $66.53 at the beginning of the year. Since then, PBE stock has decreased by 8.3% and is now trading at $61.00. View the best growth stocks for 2025 here. Who are Invesco Biotechnology & Genome ETF's major shareholders? Invesco Biotechnology & Genome ETF's top institutional shareholders include Massachusetts Wealth Management (0.51%), Farther Finance Advisors LLC (0.24%), Wealth Enhancement Advisory Services LLC (0.20%) and Pacific Sun Financial Corp (0.17%). How do I buy shares of Invesco Biotechnology & Genome ETF? Shares of PBE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Invesco Biotechnology & Genome ETF own? Based on aggregate information from My MarketBeat watchlists, some other companies that Invesco Biotechnology & Genome ETF investors own include Micron Technology (MU), Pfizer (PFE), Devon Energy (DVN), Intel (INTC), Activision Blizzard (ATVI), NVIDIA (NVDA) and Bristol-Myers Squibb (BMY). Fund Details IssuerInvesco Fund NameInvesco Biotechnology & Genome ETF Tax ClassificationRegulated Investment Company Stock ExchangeNYSEARCACurrent SymbolNYSEARCA:PBE Inception Date6/23/2005 Fund ManagerPeter Hubbard, Michael Jeanette, Pratik Doshi, Tony Seisser Webwww.invescopowershares.com Phone+1-800-9830903Fund Focus Asset ClassEquity BenchmarkDynamic Biotech & Genome Intellidex Index CategorySector FocusHealth Care Development LevelDeveloped Markets RegionNorth America Number of Holdings31 Fund Statistics Assets Under Management$216.45 million Average Daily Volume$10,513.30 Discount/Premium-0.05% Administrator, Advisor and Custodian AdministratorThe Bank of New York Mellon Corporation AdvisorInvesco Capital Management LLC CustodianThe Bank of New York Mellon Corporation DistributorInvesco Distributors, Inc. Transfer AgentThe Bank of New York Mellon Corporation TrusteeN/A Lead Market MakerCitadel Options OptionableN/A Short Interest1,500 shs Miscellaneous Outstanding Shares3,600,000Beta0.83 Creation Unit10,000 Creation Fee$500.00 Elon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free Report Top 10 PBE HoldingsNatera (NASDAQ:NTRA)Holding Weight: 5.39%Gilead Sciences (NASDAQ:GILD)Holding Weight: 5.33%Amgen (NASDAQ:AMGN)Holding Weight: 5.23%Biogen (NASDAQ:BIIB)Holding Weight: 4.64%Neurocrine Biosciences (NASDAQ:NBIX)Holding Weight: 4.59%United Therapeutics (NASDAQ:UTHR)Holding Weight: 4.58%Regeneron Pharmaceuticals (NASDAQ:REGN)Holding Weight: 4.43%Illumina (NASDAQ:ILMN)Holding Weight: 4.37%TG Therapeutics (NASDAQ:TGTX)Holding Weight: 3.94%Protagonist Therapeutics (NASDAQ:PTGX)Holding Weight: 3.73%Full Holdings DetailsPBE Sector ExposurePBE Industry Exposure This page (NYSEARCA:PBE) was last updated on 4/24/2025 by MarketBeat.com Staff From Our PartnersMost gold “analysts” aren’t really gold analysts… [watch out]People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredTrump’s Bitcoin Reserve is No Accident…Bryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new b...Crypto 101 Media | SponsoredJames Altucher: Do not invest in AI unless…I made millions during the crypto boom. Many “experts” are now saying… Artificial Intelligence opportuni...Paradigm Press | SponsoredThe Exact July Date the AI Correction Will End?AI stocks have cooled off—but Jeff Brown, the tech expert who picked Nvidia before it soared 222x, says one da...Brownstone Research | SponsoredThis Is The Moment You Betray Trump (Or Prove Them Wrong)They said you wouldn’t last—that Bidenflation, Wall Street selloffs, and DEI funds would break your loyalty to...Colonial Metals | SponsoredTrump’s treachery Forget what the media tells you. Trump’s inner circle may be pushing a financial reset that mirrors moves from...Porter & Company | SponsoredMusk’s AI Masterplan – Our #1 AI Stock to Buy NowDid Elon Musk just set the stage for the next AI stock explosion? One 30-year Wall Street veteran thinks so...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Invesco Biotechnology & Genome ETF Please log in to your account or sign up in order to add this asset to your watchlist. Share Invesco Biotechnology & Genome ETF With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.